These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22378156)

  • 41. Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients.
    Lee S; Kim JM; Chung CS; Cho KJ; Kim JH
    Arch Pharm Res; 2003 Nov; 26(11):967-72. PubMed ID: 14661864
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
    Ufer M
    Clin Pharmacokinet; 2005; 44(12):1227-46. PubMed ID: 16372822
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.
    Redman AR
    Pharmacotherapy; 2001 Feb; 21(2):235-42. PubMed ID: 11213860
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical consequences of cytochrome P450 2C9 polymorphisms.
    Kirchheiner J; Brockmöller J
    Clin Pharmacol Ther; 2005 Jan; 77(1):1-16. PubMed ID: 15637526
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of CYP4F2 polymorphisms and plasma vitamin K levels on warfarin sensitivity in Japanese pediatric patients.
    Hirai K; Hayashi H; Ono Y; Izumiya K; Tanaka M; Suzuki T; Sakamoto T; Itoh K
    Drug Metab Pharmacokinet; 2013; 28(2):132-7. PubMed ID: 22892446
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese.
    Chern HD; Ueng TH; Fu YP; Cheng CW
    Clin Chim Acta; 2006 May; 367(1-2):108-13. PubMed ID: 16413010
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Warfarin Dosing in Patients With CYP2C9*5 Variant Alleles.
    Lindley KJ; Limdi NA; Cavallari LH; Perera MA; Lenzini P; Johnson JA; Wu AHB; Ridker PM; King CR; Eby CS; Patel S; Shah SV; Beasley TM; Li J; Gage BF
    Clin Pharmacol Ther; 2022 Apr; 111(4):950-955. PubMed ID: 35108398
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California.
    London SJ; Daly AK; Leathart JB; Navidi WC; Idle JR
    Pharmacogenetics; 1996 Dec; 6(6):527-33. PubMed ID: 9014202
    [TBL] [Abstract][Full Text] [Related]  

  • 50. First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele.
    O'Brien TJ; Kidd RS; Richard CA; Ha NH; Witcher P; Tran LV; Barbour A; Tuck M; McIntosh SD; Douglas JN; Harralson AF
    Clin Chim Acta; 2013 Sep; 424():73-5. PubMed ID: 23688605
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.
    Limdi NA; Arnett DK; Goldstein JA; Beasley TM; McGwin G; Adler BK; Acton RT
    Pharmacogenomics; 2008 May; 9(5):511-26. PubMed ID: 18466099
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.
    Limdi NA; Wiener H; Goldstein JA; Acton RT; Beasley TM
    Blood Cells Mol Dis; 2009; 43(1):119-28. PubMed ID: 19297219
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.
    Wang B; Wang J; Huang SQ; Su HH; Zhou SF
    Curr Drug Metab; 2009 Sep; 10(7):781-834. PubMed ID: 19925388
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapy.
    Goldstein JA; Blaisdell JA; Limdi NA
    Blood Cells Mol Dis; 2009; 42(2):155-8. PubMed ID: 19083245
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects.
    Yin OQ; Gallagher N; Fischer D; Zhao L; Zhou W; Leroy E; Golor G; Schran H
    Clin Drug Investig; 2011; 31(3):169-79. PubMed ID: 21184622
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Warfarin dosing and cytochrome P450 2C9 polymorphisms.
    Joffe HV; Xu R; Johnson FB; Longtine J; Kucher N; Goldhaber SZ
    Thromb Haemost; 2004 Jun; 91(6):1123-8. PubMed ID: 15175798
    [TBL] [Abstract][Full Text] [Related]  

  • 57. VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients.
    Oner Ozgon G; Langaee TY; Feng H; Buyru N; Ulutin T; Hatemi AC; Siva A; Saip S; Johnson JA
    Eur J Clin Pharmacol; 2008 Sep; 64(9):889-94. PubMed ID: 18542936
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of CYP2C9, VKORC1 genotypes and old age on warfarin pharmacologic sensitivity in korean patients with thromboembolic disease.
    Moon HW; Noh J; Yun YM; Kim HY; Yun IJ; Song J; Kim JQ
    Ann Clin Lab Sci; 2011; 41(3):229-35. PubMed ID: 22075505
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human livers.
    Wang D; Sun X; Gong Y; Gawronski BE; Langaee TY; Shahin MH; Khalifa SI; Johnson JA
    Drug Metab Dispos; 2012 May; 40(5):884-91. PubMed ID: 22289258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.